Is Rivaroxaban on the market?

Rivaroxaban was originally developed byBayer Schering Pharma AG (Germany's Bayer AG). In the United States, it was developed by Janssen Pharmaceuticals (Janssen Pharmaceuticals). It was patented in 2007 and was approved by the U.S. Food and Drug Administration (FDA) for medical use in July 2011. The trade name is Xarelto, which is the first oral direct factor Xa inhibitor.

Rivaroxabanis an anticoagulant drug (blood thinner) that works by blocking the activity of the clotting protein Factor Xa and is commonly used to treat and prevent blood clots. Specifically it is used to treat deep vein thrombosis and pulmonary embolism, and to prevent blood clots after atrial fibrillation and hip or knee surgery. Common side effects include bleeding. Other serious side effects may include spinal cord hematoma and allergic reactions. It is not known whether it is safe to use during pregnancy and breastfeeding. It has fewer interactions with other medications than warfarin.

RivaroxabanThe original drug is already on the market in China and can be found under Class B medical insurance. SpecificationsThe price of 10mg*5 tablets is around RMB 100. This drug may be sold in domestic pharmacies or hospitals. The Turkish version of rivaroxabanoriginal drug marketed overseas, specifications10mg*10 tablets, is priced around RMB 170 (the price may fluctuate due to exchange rates). The ingredients of the original rivaroxaban drug sold domestically and abroad are basically the same. Currently, there are no generic drugs produced in other countries on the market overseas.